p97 is considered a drug target in certain cancers and clinical trials are under way (Anderson et al, 2015; Skrott et al, 2017; Roux et al, 2021), whereas missense mutations in p97 cause a dominantly inherited multisystem proteinopathy‐1 (MSP‐1) featuring inclusion body myopathy, Paget's disease of bone, amyotrophic lateral sclerosis, frontotemporal dementia, and Parkinsonism (Kimonis et al, 2008). This evidence concerns the gene VCP and cancer.